Sugi Predict

Sugi Predict / Compounds / SCHEMBL4154608

SCHEMBL4154608

SCHEMBL4154608

N#Cc1ccc2c(c1)CCC2N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.44
▸ LAP3 P28838 1/20 0.44
▸ DPP4 P27487 1/20 0.43
▸ DRD2 P14416 3/20 0.42
▸ DRD3 P35462 3/20 0.42
▸ PNMT P11086 1/20 0.42
▸ CYP11B1 P15538 1/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ LRRK2 Q5S007 4/20 0.41
▸ CHRNA1 P02708 1/20 0.40
▸ CHRNG P07510 1/20 0.40
▸ CHRNB1 P11230 1/20 0.40
▸ CHRNB2 P17787 1/20 0.40
▸ CHRNB4 P30926 1/20 0.40
▸ CHRNA3 P32297 1/20 0.40
▸ CHRNA4 P43681 1/20 0.40
▸ CHRND Q07001 1/20 0.40
▸ PPARD Q03181 1/20 0.39
▸ PPARA Q07869 1/20 0.39
▸ NOS3 P29474 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3131162 1.00 KDM1A (0.44) KDM1ALAP3DPP4DRD2DRD3
SCHEMBL8247897 1.00 KDM1A (0.44) KDM1ALAP3DPP4DRD2DRD3
SCHEMBL29809032 1.00 KDM1A (0.44) KDM1ALAP3DPP4DRD2DRD3
SCHEMBL30487209 1.00 KDM1A (0.44) KDM1ALAP3DPP4DRD2DRD3
SCHEMBL30894874 1.00 KDM1A (0.44) KDM1ALAP3DPP4DRD2DRD3
Hydrochloric Acid SCHEMBL4046623 0.98 LAP3 (0.46) KDM1ALAP3DPP4DRD2DRD3
Hydrochloric Acid SCHEMBL22371915 0.98 LAP3 (0.46) KDM1ALAP3DPP4DRD2DRD3
Hydrochloric Acid SCHEMBL1271612 0.98 LAP3 (0.46) KDM1ALAP3DPP4DRD2DRD3
Hydrochloric Acid SCHEMBL5270193 0.98 LAP3 (0.46) KDM1ALAP3DPP4DRD2DRD3
Hydrochloric Acid SCHEMBL29558222 0.98 LAP3 (0.46) KDM1ALAP3DPP4DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368652-A1 MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2025-12-04 — — US disclosed
EP-4380932-B1 PROCESS FOR PREPARING AFICAMTEN CYTOKINETICS INC (US) 2025-11-26 — — EP disclosed
US-12247024-B2 Process for preparing aficamten CYTOKINETICS, INC. (US) 2025-03-11 — — US disclosed
US-20240150336-A1 PROCESS FOR PREPARING AFICAMTEN CYTOKINETICS, INC. 2024-05-09 — — US disclosed
CN-117813304-A Method for preparing alfukanitai 赛特凯恩蒂克公司 2024-04-02 — — CN disclosed
US-11932631-B2 Process for preparing aficamten CYTOKINETICS, INC. (US) 2024-03-19 — — US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 — — US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 — — US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 — — US disclosed
WO-2023015184-A1 PROCESS FOR PREPARING AFICAMTEN CYTOKINETICS, INC. (US) 2023-02-09 — — WO disclosed
US-7553861-B2 Dipeptidyl peptidase-IV inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-06-30 — — US disclosed
US-20090048224-A1 COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2009-02-19 — — US disclosed
US-7425631-B2 Compounds and methods of use AMGEN INC. (US) 2008-09-16 — — US disclosed
WO-2006116157-A9 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS INC (US) 2007-03-01 — — WO disclosed
WO-2006116157-A2 DIPEPTIDYL PEPTIDASE-IV INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2006-11-02 — — WO disclosed
EP-1633743-A1 CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ Amgen, Inc. (US) 2006-03-15 — — EP disclosed
EP-1631542-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF Amgen, Inc. (US) 2006-03-08 — — EP disclosed
US-20050124654-A1 Compounds and methods of use AMGEN INC. 2005-06-09 — — US disclosed
WO-2004092164-A1 CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ AMGEN, INC. (US) 2004-10-28 — — WO disclosed
WO-2004092116-A1 BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF AMGEN, INC. (US) 2004-10-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124654-A1 Compounds and methods of use LTC4S, PTGES, LTB4R2 KDM1A 3729/4885LAP3 1265/4885DPP4 316/4885
US-20250368652-A1 MICROBIOCIDAL BICYCLIC HETEROCYCLIC CARBOXAMIDE DERIVATIVES CASP1, ARG2, MPO KDM1A 501/4885LAP3 1448/4885DPP4 220/4885
US-20090048224-A1 COMPOUNDS AND METHODS OF USE LTC4S, PTGES, LTB4R2 KDM1A 3729/4885LAP3 1265/4885DPP4 316/4885
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS LRRK2, PARK7, GDI2 KDM1A 1182/4885LAP3 1505/4885DPP4 3375/4885
US-11932631-B2 Process for preparing aficamten INMT, PNMT, NNMT KDM1A 148/4885LAP3 2149/4885DPP4 1182/4885
US-20240150336-A1 PROCESS FOR PREPARING AFICAMTEN INMT, PNMT, NNMT KDM1A 156/4885LAP3 2152/4885DPP4 1197/4885
US-12247024-B2 Process for preparing aficamten INMT, PNMT, NNMT KDM1A 148/4885LAP3 2149/4885DPP4 1182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.